Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration ...

HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Analysts expect Hookipa Pharma to post earnings of ($0.61) per share and revenue of $3.38 million for the quarter. Hookipa Pharma Trading Up 15.6 % HOOK opened at $1.48 on Wednesday.

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which ...

I wonder are Gilead interested in us any more as they ... announcing a brand new dream deal from a third party and the HOOKIPA one dropped last night was just to save face from them.

Following the completion of the Phase 1b trial, Gilead will have the exclusive right to further develop the program.

The Combined Group would also have two partnered programmes with Gilead Sciences ... for the Combined Group's shareholders. HOOKIPA is listed on the Nasdaq Capital Market under the symbol HOOK ...

On a fully diluted basis, The CVR is expected to provide that HOOKIPA Shareholders will be entitled to approximately (i) 55% of the milestone payments made by Gilead to HOOKIPA following the ...